AN2 Therapeutics, Inc. Common Stock (ANTX)
AN2 Therapeutics, Inc. (ANTX) is a biopharmaceutical company focused on developing targeted therapies for neurodegenerative and neurological disorders. The company’s research centers on innovative approaches to treat diseases such as Alzheimer's and other cognitive impairments, aiming to address unmet medical needs through novel small molecule and biologic programs.
Dividend History
| Pay Date | Amount | Ex-Date | Record Date |
|---|---|---|---|
| May 1, 2018 | $0.66 | 2018-04-12 | 2018-04-15 |
| February 1, 2018 | $0.66 | 2018-01-11 | 2018-01-15 |
| November 1, 2017 | $0.66 | 2017-10-12 | 2017-10-15 |
| August 1, 2017 | $0.66 | 2017-07-12 | 2017-07-15 |
| May 1, 2017 | $0.66 | 2017-04-11 | 2017-04-15 |
Dividends Summary
- AN2 Therapeutics, Inc. Common Stock has issued 12 dividend payments over the past 3 years
- The most recent dividend was paid 2732 days ago, on May 1, 2018
- The highest dividend payed out to investors during this period was $0.66 per share
- The average dividend paid during this period was $0.65 per share.
Company News
AN2 Therapeutics (ANTX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page. Keybanc raised the price target for monday.com Ltd. (NASDAQ: MNDY) from $238 to $242. Keybanc analyst Jason Celino maintained an Overweight rating. monday.c...
MENLO PARK, Calif., Oct. 06, 2022 (GLOBE NEWSWIRE) -- AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical-stage biopharmaceutical company focused on developing treatments for rare, chronic, and serious infectious diseases with high unmet needs, today provided an update on the ex-U.S. development plan for epetraborole in treatment-refractory Mycob...